Drug class
Levodopa prodrug; dopamine precursor component of the foscarbidopa/foslevodopa combination
Mechanism of action
Foslevodopa is converted to levodopa, which crosses the blood-brain barrier and is decarboxylated to dopamine in the brain. It is administered with foscarbidopa to inhibit peripheral levodopa conversion and support continuous subcutaneous delivery.
General use cases
- Component of the fixed combination VYALEV (foscarbidopa/foslevodopa) for treatment of motor fluctuations in adults with advanced Parkinson disease; not a stand-alone approved indication
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
